Dashboard
1
Poor Management Efficiency with a low ROCE of 1.82%
- The company has been able to generate a Return on Capital Employed (avg) of 1.82% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -0.11% and Operating profit at -6.87% over the last 5 years
3
The company has declared Negative results for the last 4 consecutive quarters
4
With ROE of 8.56%, it has a attractive valuation with a 1.17 Price to Book Value
5
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,484 Million (Small Cap)
14.00
NA
2.18%
-0.40
7.81%
1.10
Revenue and Profits:
Net Sales:
385 Million
(Quarterly Results - Dec 2025)
Net Profit:
48 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.77%
0%
11.77%
6 Months
5.02%
0%
5.02%
1 Year
39.36%
0%
39.36%
2 Years
35.84%
0%
35.84%
3 Years
3.97%
0%
3.97%
4 Years
38.32%
0%
38.32%
5 Years
83.11%
0%
83.11%
Tianjin Lisheng Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.11%
EBIT Growth (5y)
-6.87%
EBIT to Interest (avg)
34.34
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.25
Tax Ratio
14.16%
Dividend Payout Ratio
48.50%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.82%
ROE (avg)
3.32%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.17
EV to EBIT
96.31
EV to EBITDA
31.37
EV to Capital Employed
1.29
EV to Sales
2.91
PEG Ratio
0.91
Dividend Yield
1.10%
ROCE (Latest)
1.34%
ROE (Latest)
8.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
384.70
275.80
39.49%
Operating Profit (PBDIT) excl Other Income
32.90
42.90
-23.31%
Interest
0.30
0.60
-50.00%
Exceptional Items
-0.30
2.60
-111.54%
Consolidate Net Profit
48.40
28.90
67.47%
Operating Profit Margin (Excl OI)
34.00%
83.70%
-4.97%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 39.49% vs -22.46% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 67.47% vs -89.99% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,379.60
1,325.00
4.12%
Operating Profit (PBDIT) excl Other Income
173.20
147.60
17.34%
Interest
2.90
3.60
-19.44%
Exceptional Items
-1.90
16.30
-111.66%
Consolidate Net Profit
422.70
186.00
127.26%
Operating Profit Margin (Excl OI)
68.00%
50.10%
1.79%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 4.12% vs 16.09% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 127.26% vs -48.59% in Dec 2024
About Tianjin Lisheng Pharmaceutical Co., Ltd. 
Tianjin Lisheng Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






